Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, CAR-T, and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ICAM2/CD102 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ICAM2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ICAM2 Products |
| Gene Delivery | ICAM2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ICAM2 Products |
| Benchmark Ab | Anti-ICAM2 (Sequence of Clinical Reference) Recombinant positive control. |
View ICAM2 Products |
| Validator | ICAM2 siRNA Set For knockdown verification. |
View ICAM2 Products |
| Related Target A | ICAM1 High homology counter-screening to ensure drug selectivity. |
View ICAM1 Products |
| Related Target B | ITGAL LFA-1 alpha subunit, the primary physiological ligand of ICAM2. |
View ITGAL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter screening (ICAM1/ICAM3) | Homolog panel proteins strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ICAM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ICAM2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to cell therapies (CAR-T) and bispecific antibodies. As first-generation therapies targeting tumor vasculature and immune evasion reach the clinic, the next wave of R&D is targeting tumor-specific conformation changes and combination therapies with immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / Cell Therapy | Academic Institutions, Biotech Startups | Neuroblastoma, AML, Solid Tumors | Target expression density & activation assay (Need Lentivirus for Stable Cell Lines) |
| Bispecific Antibodies | Immuno-oncology Biopharma | Metastatic Colorectal Cancer | Heterodimer Validation & bridging assays (Need Cross-reactive Abs) |
| Monoclonal Antibodies | Angiogenesis-focused Pharma | Solid Tumors, Inflammatory Disorders | Ligand-blocking assays (Need high-purity ECD-Fc proteins) |